Jan. 13, 2021 13:00 UTC
NEW YORK–(BUSINESS WIRE)– Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric oncology clinical trial enrollment, announced today it has launched its SYNERGY-AI Oncology Clinical Trial Command Center (OCTCC) with the mission to disrupt and accelerate the clinical trial enrollment process. Akin to the NASA Deep Space Network, SYNERGY-AI OCTCC is a real time data and communication network between patients, sites, and pharmaceutical companies, with the Massive Bio AI-enabled engine orchestrating these stakeholders for successful operations. SYNERGY-AI OCTCC also coordinates instant patient identification through two dozen direct and in-direct patient identification channels, privacy-compliant AI-based patient pre-screening, enrollment concierge, and just-in-time site activation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005051/en/
SYNERGY-AI Oncology Clinical Trial Command Center (OCTCC) (Photo: Business Wire)
Massive Bio had previously announced the launch of the Largest AI Enabled Just-in-Time Precision Oncology Clinical Trial Network in The World, the contract by the National Cancer Institute (NCI) to develop and characterize the Deep Learning Clinical Trial Matching System (DLCTMS), the launch of its trial finder mobile app, and its successful SOC 2 certification. Following its most recent financing round, Massive Bio’s trial enrollment platform has been evolving into a command center to supply research stakeholders with real-time communications, data, and enhanced analytics.
“The same way NASA manages space flights, usually from the point of launch until the end of the mission, Massive Bio’s command center is taking its program to the next level by using data, analytics, patient engagement, and research site networks to coordinate patient enrollment and site activation in real-time,” said Selin Kurnaz, PhD., Co-founder and CEO of Massive Bio. “History is being written today as we embark on our ambitious mission to kickstart the renaissance in oncology clinical trial enrollment. We are all aware that the process between patient identification and enrollment is significantly inefficient and ineffective, especially for those patients that are currently not getting treatment in research-oriented sites. Static and siloed big data, obsolete databases, and traditional clinical trial matching platforms within healthcare are yielding sub-optimal results. Thus, we analyzed the world’s most sensitive, well-coordinated and error free platforms, like the NASA Deep Space Network, combined them with clinical research and engineering, applied them to the oncology clinical trial enrollment, and that is how Massive Bio’s command center is coming to life.” Dr. Kurnaz also stated, “We understand that we are signing up for an earth shatteringly difficult task – this is a multi-year effort that requires a multi-pronged approach, and we have been preparing for this launch over the last couple of years. In our vision, a cancer patient taps to his/her smart device to activate all required pre-screening procedures and gets into his/her autonomous vehicle to complete the non-home-based vital portion of the clinical research process within less than 30-minutes driving distance site, while trial education, physician coordination, consent, pre-screening, logistics coordination, insurance verification, and site activation are taking place simultaneously prior to arrival. Eventually, this is also going to revolutionize how fast an oncology drug can hit the market and introduce further competition to the pharmaceutical industry.”
While SYNERGY-AI OCTCC materially optimizes workflow efficiencies for global pharmaceutical companies and contract research organizations, it also supports Massive Bio in performing in silico clinical trial enrollment simulations through…